rs750518671

Variant summary

Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PM5PP5_Very_Strong

The NM_000527.5(LDLR):​c.2389G>A​(p.Val797Met) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000434 in 1,613,688 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V797L) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000034 ( 0 hom. )

Consequence

LDLR
NM_000527.5 missense, splice_region

Scores

2
4
8
Splicing: ADA: 0.9997
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:19U:3

Conservation

PhyloP100: 2.41
Variant links:
Genes affected
LDLR (HGNC:6547): (low density lipoprotein receptor) The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 12 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr19-11128085-G-T is described in Lovd as [Likely_pathogenic].
PP5
Variant 19-11128085-G-A is Pathogenic according to our data. Variant chr19-11128085-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 226393.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-11128085-G-A is described in Lovd as [Pathogenic]. Variant chr19-11128085-G-A is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LDLRNM_000527.5 linkc.2389G>A p.Val797Met missense_variant, splice_region_variant Exon 16 of 18 ENST00000558518.6 NP_000518.1 P01130-1A0A024R7D5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LDLRENST00000558518.6 linkc.2389G>A p.Val797Met missense_variant, splice_region_variant Exon 16 of 18 1 NM_000527.5 ENSP00000454071.1 P01130-1

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
152078
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000796
AC:
2
AN:
251360
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
135890
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000342
AC:
5
AN:
1461610
Hom.:
0
Cov.:
32
AF XY:
0.00000413
AC XY:
3
AN XY:
727120
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.0000232
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000132
AC:
2
AN:
152078
Hom.:
0
Cov.:
31
AF XY:
0.0000135
AC XY:
1
AN XY:
74296
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000207
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.00000378
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:19Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hypercholesterolemia, familial, 1 Pathogenic:11Uncertain:3
Nov 05, 2016
Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 24, 2021
Laboratory of molecular diagnosis of dyslipidemias, Università egli studi di Napoli Federico II
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Affects splicing, IVS16 ds -1 G>A. -

Mar 25, 2024
All of Us Research Program, National Institutes of Health
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This missense variant changes the last nucleotide c.G of exon 16 of the LDLR gene and is predicted to impair RNA splicing at the intron 16 splice donor site. This variant is also known as p.Val776Met in the mature protein. RNA studies from carrier individuals have shown that this variant causes skipping of exon 16 (PMID: 34497632), and leads to absence of wild-type transcript (PMID: 9763532). In vitro functional studies have shown that this variant causes a reduction in LDLR internalization and expression at the cellular membrane (PMID: 34497632). This variant has been reported in over 20 heterozygous individuals affected with familial hypercholesterolemia (PMID: 7649549, 9763532, 18718593, 19446849, 20145306, 22698793, 22859806, 23375686, 27816806, 33418990, 33794673, 34497632). This variant has also been observed in homozygous state in two individuals affected with severe homozygous familial hypercholesterolemia (PMID: 33093846, 36229885). It has been shown that this variant segregates with disease in multiple affected individuals across two families (PMID: 7649549, 34497632). This variant has been identified in 2/251360 chromosomes in the general population by the Genome Aggregation Database (gnomAD). A different variant affecting the same codon, c.2389G>T (p.Val797Leu), is considered to be disease-causing (ClinVar variation ID: 252298), suggesting that valine at this position is important for LDLR protein function. Based on the available evidence, this variant is classified as Pathogenic. -

Apr 12, 2013
Cardiovascular Genetics Laboratory, PathWest Laboratory Medicine WA - Fiona Stanley Hospital
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Mar 01, 2016
Iberoamerican FH Network
Significance: Uncertain significance
Review Status: flagged submission
Collection Method: research

- -

Mar 25, 2016
LDLR-LOVD, British Heart Foundation
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: literature only

- -

Mar 01, 2016
Laboratory of Genetics and Molecular Cardiology, University of São Paulo
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

- -

Mar 01, 2016
Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge
Significance: Uncertain significance
Review Status: flagged submission
Collection Method: research

0/150 non-FH alleles; 0/100 healthy control individuals; 0/60 healthy control individuals -

Dec 16, 2016
Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

subjects mutated among 2600 FH index cases screened = 4 , family members = 6/previously described in association with FH/Software predictions: Benign -

Jan 18, 2023
Revvity Omics, Revvity
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: research

- -

Mar 30, 2017
U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 01, 2016
Fundacion Hipercolesterolemia Familiar
Significance: Uncertain significance
Review Status: flagged submission
Collection Method: research

- -

-
Suma Genomics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Pathogenic:3
Mar 08, 2021
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant has been reported in multiple index patients with hypercholesterolemia in the published literature (PMID: 31491741 (2019), 23375686 (2013), 22698793 (2012), 20538126 (2010), 20145306 (2010), 18718593 (2009)). One family study indicated the variant strongly segregated with disease (PMID: 7649549 (1995)). In addition, this variant is located at an exon-intron junction and an RT-PCR study suggests the variant may affect LDLR mRNA splicing (PMID: 9763532 (1998)). Based on the available information, this variant is classified as pathogenic. -

Oct 05, 2023
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Not observed at significant frequency in large population cohorts (gnomAD); Published function studies demonstrate decreased residual receptor activity in cultured fibroblasts of FH heterozygotes (Guardamagna et al., 2009); Functional splice studies of a different variant at this same nucleotide position (c.2389 G>T, p.V797L) demonstrate skipping of exon 16, further supporting the functional importance of this nucleotide position (Bourbon et al., 2009); Also known as p.(V776M); This variant is associated with the following publications: (PMID: 16314194, 32759540, 30526649, 34037665, 9763532, 7649549, 11810272, 12436241, 28104544, 29233637, 27816806, 23375686, 21310417, 19318025, 20145306, 20538126, 15199436, 22859806, 22698793, 15701167, 18718593, 29874871, 27821657, 31491741, 31447099, 35339733, 34297352, 36229885, 32977124, 32331935, 33740630, 34497632, 35910211, 35913489, 35480308, 28169869, 19446849, 30710474, 33994402, 36991406, 37482509) -

Jan 01, 2023
Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The LDLR c.2389G>A (p.Val797Met) variant involves the alteration of a conserved nucleotide located at the last nucleotide of exon 16.This variant has been found in several FH patients including evidence of cosegregation with disease. -

Familial hypercholesterolemia Pathogenic:3
May 13, 2018
Color Diagnostics, LLC DBA Color Health
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Pathogenic variant based on current evidence: This variant (also known as p.Val776Met in the mature protein) changes the last nucleotide in exon 16 of the LDLR mRNA (c.2389G>A). This conserved G at the last nucleotide position of an exon is known to play an important role in splicing. Although detailed splice analysis has not been performed for this variant, one study has indicated that this variant causes splicing defect and leads to absent of transcript (PMID: 9763532). A different variant at the same position (c.2389G>T) has been shown to cause an in-frame skipping of exon 16 that encodes the transmembrane domain of the LDLR protein. This demonstrates the importance of the c.2389G nucleotide in the correct splicing at the exon 16-intron 16 splice region. While this variant is rare in the general population (2/246210 chromosomes in the Genome Aggregation Database, gnomAD), it has been reported in 10+ unrelated individuals affected with familial hypercholesterolemia (PMID: 18718593, 19446849, 20145306, 22698793, 23375686). In addition, this variant has been shown to segregate with disease in 10 members from a Cuban family with familial hypercholesterolemia (PMID: 7649549). Based on available evidence, this variant is classified as Pathogenic. -

Jun 21, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: The LDLR c.2389G>A (p.Val797Met) variant involves the alteration of a conserved nucleotide located at the last nucleotide of exon 16. 2/4 in silico tools predict benign outcome for this variant but 5/5 splice prediction tools predict a significant impact on normal splicing. A reverse transcriptionPCR study indicated that it is likely to cause a donor site splicing error (Mak_1998). This variant was found in 1/121374 control chromosomes (including ExAC) at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic LDLR variant (0.0012508). This variant has been found in several FH patients including evidence of cosegregation with disease. Multiple clinical diagnostic laboratories/reputable databases have classified this variant as likely pathogenic/pathogenic. Taken together, this variant is classified as pathogenic. -

Dec 17, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 797 of the LDLR protein (p.Val797Met). This variant also falls at the last nucleotide of exon 16, which is part of the consensus splice site for this exon. This variant is present in population databases (rs750518671, gnomAD 0.003%). This missense change has been observed in individuals with familial hypercholesterolemia (PMID: 7649549, 9763532, 19446849, 20145306, 22698793, 22859806, 23375686). It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this LDLR variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 363,995 individuals referred to our laboratory for LDLR testing. ClinVar contains an entry for this variant (Variation ID: 226393). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -

Homozygous familial hypercholesterolemia Pathogenic:1
Mar 29, 2019
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.Val797Met variant in LDLR has been reported in the heterozygous, homozygous, or compound heterozygous state in >10 individuals with familial hypercholesterolemia (FH), segregating with disease in at least 15 affected relatives from 4 families (Pereira, 1995, Mak 1998, Tichy 2012, Bertolini 2013, Setia 2016, Leren 2004). This variant has also been reported in Clinvar (Variation ID 226393). This variant has been identified in 1/30782 South Asian chromosomes by the genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs750518671). This variant is located in the last base of the exon, which is part of the 5’ splice region and has been shown to cause altered splicing leading to absent protein (Mak 1998). Heterozygous loss of function of the LDLR gene is an established disease mechanism in FH. In summary, this variant meets our criteria to be classified as pathogenic for familial hypercholesterolemia in an autosomal dominant manner based upon presence in affected individuals, segregation studies, low frequency in the general population and the demonstrated impact to the protein. -

Cardiovascular phenotype Pathogenic:1
Sep 12, 2024
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.2389G>A pathogenic mutation (also known as p.V797M), located in coding exon 16 of the LDLR gene, results from a G to A substitution at nucleotide position 2389. The amino acid change results in valine to methionine at codon 797, an amino acid with highly similar properties. This change occurs in the last base pair of coding exon 16, which makes it likely to have some effect on normal mRNA splicing. This alteration (also referred to as p.V776M) has been reported in a number of individuals of different origins with familial hypercholesterolemia (Pereira E et al. Hum. Genet., 1995 Sep;96:319-22; Mak YT et al. Arterioscler. Thromb. Vasc. Biol., 1998 Oct;18:1600-5; Fouchier SW et al. Hum. Genet., 2001 Dec;109:602-15; Leren TP et al. Semin Vasc Med, 2004 Feb;4:75-85; Robles-Osorio L et al. Arch. Med. Res., 2006 Jan;37:102-8; Bourbon M et al. Atherosclerosis, 2008 Feb;196:633-42; Alonso R et al. Clin. Biochem., 2009 Jun;42:899-903; Guardamagna O et al. J. Pediatr., 2009 Aug;155:199-204.e2; Chmara M et al. J. Appl. Genet., 2010;51:95-106; Chiou KR et al. Am. J. Cardiol., 2010 Jun;105:1752-8; Setia N et al. Atherosclerosis, 2016 Dec;255:31-36; Durst R et al. Atherosclerosis, 2017 Feb;257:55-63). In addition, this alteration segregated with the disease in a multi-generation family (Pereira E et al. Hum. Genet., 1995 Sep;96:319-22). One study suggested that this alteration would affect the splicing as only the wild type allele was detected by the reverse transcription (Mak YT et al. Arterioscler. Thromb. Vasc. Biol., 1998 Oct;18:1600-5). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.17
BayesDel_addAF
Pathogenic
0.17
D
BayesDel_noAF
Uncertain
0.050
CADD
Uncertain
24
DANN
Benign
0.97
Eigen
Benign
0.010
Eigen_PC
Benign
0.033
FATHMM_MKL
Uncertain
0.94
D
LIST_S2
Benign
0.31
T
M_CAP
Pathogenic
0.75
D
MetaRNN
Benign
0.38
T
PROVEAN
Benign
0.24
N
Sift
Uncertain
0.0060
D
Sift4G
Uncertain
0.014
D
Vest4
0.15
MVP
1.0
ClinPred
0.19
T
GERP RS
4.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.8

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.93
SpliceAI score (max)
0.32
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.32
Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs750518671; hg19: chr19-11238761; API